Viking Therapeutics (VKTX)

Company Description

Viking Therapeutics is a mid-clinical stage biotech company focused on development of therapeutics for endocrinological and orphan diseases near term. The company currently has two lead products in development: 1) VK5211, a non-steroidal selective androgen receptor modulator (SARM) that VKTX is starting post hip fracture surgery rehabilitation Phase II study in 3Q15 with top-line results expected in 2Q16; and 2) a thyroid β agonist, either VK0214 or VK2809, to be used as a potential treatment for X-linked adrenoleukodystrophy (X-ALD) with adrenomyeloneuropathy (AMN) subtype. A Phase I study is scheduled to start in 1Q16 with top-line results expected in mid- to 2H16. In addition, VKTX also has multiple clinical assets to be further developed once the company obtains more financial support. These assets include: 1) VK2809 in dyslipidemias, for which it has already exhibited positive results from a Phase Ib trial, and NASH; 2) VK0612, a Phase IIb-ready drug candidate for type 2 diabetes) 3) an EPO receptor (EPOR) agonist program in pre-clinical development as a potential treatment of anemia; and 4) a diacylglycerol acyltransferase-1 (DGAT-1) inhibitor program, which is pre-clinical as a potential treatment of lipid disorders such as obesity and dyslipidemia.

Published Reports

VKTX-2018-11-08-3Q18
VKTX-2018-10-01-VK5211 ASBMR presentation
VKTX-2018-09-19-VK2809 P2 readout robust
VKTX-2018-08-10-2Q18
VKTX-2018-06-01-TP increased
VKTX-2018-05-10-1Q18
VKTX-2018-03-08-VKTX reported 4Q17 financial results
VKTX-2017-11-29-positive VK5211 P2 readout
VKTX-2017-11-09-3Q17
VKTX-2017-10-10-Musculoskeletal KOL day
VKTX-2017-08-10-2Q17 rev
VKTX-2017-05-11-1Q17 rev
VKTX-2017-03-22-4Q16 rev
vktx-2016-11-11-3q16-rev
VKTX-2016-08-11-2Q16 rev
VKTX-2016-07-26-VK0214 in X-ALD preclinical data rev
VKTX-2016-05-11-1Q16 rev
VKTX-2016-03-09-4Q15
VKTX-2015-12-07-VK5211 poster
VKTX-2015-11-17-VK2809 P2 trial to start
VKTX-2015-11-05-3Q15
VKTX-2015-11-03-VK5211 P2 started rev
VKTX-2015-09-14-Mgnt update
VKTX-2015-10-20-VK5211-P2-to-start-4Q15-rev
VKTX-2015-08-13-2Q15 rev
VKTX-2015-07-29-VK2809in cholesterolemia P2
VKTX-2015-07-15-VK5211 P2 IND submitted rev
VKTX-2015-06-08-Initiation-Final rev2